The Institute was proposing that TA238 and TA302 should be updated in an MTA, which would consider both the intravenous and subcutaneous formulations of tocilizumab and canakinumab for the treatment of systemic juvenile arthritis.

After consideration of all of the comments received during the review consultation, the technology appraisals programme has decided to proceed with this proposal.

Consequently, a review of TA238 and TA302 will be planned into the technology appraisals work programme to coincide with the timing of any future extension to the marketing authorisation for the subcutaneous formulation for tocilizumab for systemic juvenile idiopathic arthritis. The technologies will be appraised through the multiple technology appraisal (MTA) process.

April 2015

Attachments: